Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6167379 | Urology | 2013 | 7 Pages |
Abstract
Obese men with prostate cancer were no more likely to have a higher prebiopsy PSA level, Gleason score, clinical T stage, or D'Amico risk than those of normal weight. Although we do not know whether the BMI affected the prebiopsy PSA values in those without a diagnosis of prostate cancer, our findings suggest that the BMI does not affect the interpretation of the prebiopsy PSA levels in those with cancer.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Karim Chamie, Stephanie Oberfoell, Lorna Kwan, Jessica Labo, John T. Wei, Mark S. Litwin,